The novel mTOR inhibitor RAD001 (Everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells [PDF]
, 2007 Background/Aim: Tumors exhibiting constitutively activated PI(3) K/Akt/mTOR signaling are hypersensitive to mTOR inhibitors such as RAD001 (everolimus) which is presently being investigated in clinical phase II trials in various tumor entities, including
Albert JM +35 more
core +1 more source
mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors [PDF]
Endocrine-Related Cancer, 2016 Medical therapy of pancreatic neuroendocrine tumors (P-NET) may take advantage of Everolimus treatment. However, the extent of therapeutic response cannot be predicted. This study was aimed to identify the possible predictive markers of response to Everolimus in P-NET. We found that Everolimus reduced the cell viability and induced apoptosis in primary
FALLETTA, Simona +11 more
openaire +3 more sources
Rapamycin induces transactivation of the EGFR and increases cell survival. [PDF]
, 2009 The mammalian target of rapamycin (mTOR) signaling network regulates cell growth, proliferation and cell survival. Deregulated activation of this pathway is a common event in diverse human diseases such as cancers, cardiac hypertrophy, vascular ...
Chaturvedi, D +4 more
core +2 more sources
mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
Cell & Bioscience, 2020 Mammalian target of rapamycin (mTOR) regulates cell proliferation, autophagy, and apoptosis by participating in multiple signaling pathways in the body. Studies have shown that the mTOR signaling pathway is also associated with cancer, arthritis, insulin
Zhilin Zou +3 more
doaj +1 more source
Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. [PDF]
, 2014 Understanding genetic aberrations in cancer leads to discovery of new targets for cancer therapies. The genomic landscape of hepatocellular carcinoma (HCC) has not been fully described. Therefore, patients with refractory advanced/metastatic HCC referred
Janku, Filip +4 more
core +3 more sources
mTOR inhibitors in cancer therapy
F1000Research, 2016 The mammalian target of rapamycin, mTOR, plays key roles in cell growth and proliferation, acting at the catalytic subunit of two protein kinase complexes: mTOR complexes 1 and 2 (mTORC1/2). mTORC1 signaling is switched on by several oncogenic signaling pathways and is accordingly hyperactive in the majority of cancers.
Jianling Xie +2 more
openaire +2 more sources
PRAS40 suppresses atherogenesis through inhibition of mTORC1-dependent pro-inflammatory signaling in endothelial cells [PDF]
, 2019 Endothelial pro-inflammatory activation plays a pivotal role in atherosclerosis, and many pro-inflammatory and atherogenic signals converge upon mechanistic target of rapamycin (mTOR).
Althoff, Till F. +14 more
core +1 more source
Turkish Journal of NephrologyBackground: Dysfunction of the mammalian target of the rapamycin (mTOR) signaling pathway by mTOR inhibitors in kidney transplant recipients (KTRs) may contribute to sarcopenia in addition to metabolic factors and infammation.
Merve Güner +11 more
doaj +1 more source
Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells
BMC Cancer, 2012 Background The mammalian target of rapamycin (mTOR) is frequently activated in colon cancers due to mutations in the phosphatidylinositol 3-kinase (PI3K) pathway.
Blaser Benjamin +6 more
doaj +1 more source
A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers. [PDF]
, 2016 mTOR inhibition has emerged as a promising strategy for head and neck squamous cell carcinomas (HNSCC) treatment. However, most targeted therapies ultimately develop resistance due to the activation of adaptive survival signaling mechanisms limiting the ...
Amornphimoltham, Panomwat +10 more
core +1 more source